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ABSTRACT
EFFECTS OF A NOVEL, NON-TOXIC HISTONE DEACETYLASE INHIBITOR ON
HIPPOCAMPAL MEMORY FORMATION, HISTONE ACETYLATION, AND BDNF
GENE EXPRESSION IN MALE MICE
by
Sarah Beamish
The University of Wisconsin-Milwaukee, 2021
Under the Supervision of Dr. Karyn Frick
Memory dysfunction is a common symptom of aging, neuropsychiatric disorders,
and neurodegenerative disorders, yet truly effective treatments for memory loss do not
exist. De novo gene transcription is a molecular requirement for long-term memory
formation. The transcription of genes related to synaptic plasticity and learning is
regulated in part by histone acetylation, an epigenetic mechanism that regulates
chromatin accessibility. Pharmacological compounds that maintain histone acetylation,
called histone deacetylase inhibitors (HDACi), enhance memory by preventing
deacetylation of core histone proteins, which initiates binding of transcriptional
machinery to open chromatin. Therefore, HDACi are potentially promising therapeutics
that could be used to prevent or delay memory loss associated with aging and other
disorders. However, existing HDACi have poor solubility and undesirable toxicity. We
collaborated with Drs. Mahmun Hossain and Doug Steeber of the University of
Wisconsin-Milwaukee to develop a novel brain-penetrant HDACi compound, MJM-1,
that shows minimal toxicity and is capable of crossing the blood brain barrier. The goal
of this study was to determine the extent to which MJM-1 enhances spatial and object
recognition memory consolidation, alters hippocampal histone acetylation, and modifies
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hippocampal bdnf expression in male mice. Here, we demonstrate that post-training i.p.
administration of MJM-1 enhances hippocampal-dependent spatial, but not object
recognition, memory consolidation in male mice. Interestingly, however, we observed no
treatment effects of MJM-1 on hippocampal histone acetylation when administered
alone or immediately following object training. Finally, we also demonstrated that MJM-1
did not alter hippocampal expression of bdnf exons I or IV. Our results suggest that
MJM-1 likely enhances spatial memory consolidation by affecting acetylation states of
nonhistone proteins. These results underscore the need to better understand the ways
in which systemic HDACi administration affects numerous other nonhistone substrates
that can also promote beneficial effects on cognition.
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INTRODUCTION
Chromatin and Histone Acetylation
The term epigenetics has historically been used to describe the ways in which
genes interact with their environment to produce a particular phenotype (Waddington
1942). Epigenetic modifications serve to regulate experience-dependent changes in gene
expression that are independent of the actual genome sequence itself (Bird 2007).
Chromatin is composed of DNA that is wrapped around a core histone octamer which
contains two copies each of the histone proteins H2A, H2B, H3, and H4. Epigenetic
modifications serve to regulate the compaction and relaxation of chromatin by modifying
the strength of interactions between DNA and core histone proteins (Kim & Kaang, 2017).
One of the most well studied epigenetic alterations that alters learning and memory is
histone acetylation, a process in which acetyl groups are added to lysine residues on the
N-terminal tails of histone proteins (Figure 1). The positive charges of unmodified histone
proteins promote a tight interaction with negatively charged DNA which promote a
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Figure 1. Histone acetylation and deacetylation is mediated
by HATs and HDACs, respectively. In eukaryotic cells, DNA is
wrapped around core histone proteins. The N-terminal tails of
histone proteins can become acetylated at specific lysine
residues by HATs, which increase chromatin accessibility.
HDACs remove acetyl groups and increase compaction of
chromatin.
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HATs weakens the electrostatic affinity between histones and negatively charged DNA,
effectively relaxing the chromatin structure so that it is more permissive for gene
transcription. Conversely, the removal of acetyl groups by HDACs restores the strong
electrostatic affinity between histone and DNA, effectively repressing gene transcription
(Strahl & Allis, 2000). Therefore, chromatin is considered to be a highly plastic substrate
that is capable of responding to changes in neuronal signaling that support cognition
(Haggarty & Tsai, 2011).
Established Classes of Histone Deacetylases and Their Inhibitors
The superfamily of HDACs consists of eighteen HDAC isoforms categorized into
four classes: class I, II, IV, and the structurally distinct class III (Gregoretti et al., 2004).
The classes of HDACs differ among their catalytic sites, expression across cell types, as
well as their subcellular localization (Penney & Tsai, 2014). Class I, II, and IV HDACs are
zinc (Zn2+)-dependent enzymes, whereas class III HDACs are nicotinamide adenine
dinucleotide (NAD+)-dependent enzymes. The Zn2+- and NAD+-dependent catalytic sites
play a crucial role in targeting HDACi to the active site of HDACs, and thus, are central
pieces of the scaffold in designing isoform-specific HDACis (Zhang et al., 2018). Class I
HDACs (HDAC1, 2, 3, and 8) are primarily found within the nucleus and are ubiquitously
expressed throughout cell types, with the exception of HDAC8, which is largely musclespecific (Waltregny et al., 2005; Xu et al., 2011) Interestingly, class I HDACs are
extensively expressed in neurons within the rat hippocampus, amygdala, and other
cortical areas, all of which are all critical brain regions involved in learning and memory
(Broide et al., 2007). As such, class I HDACs have been the most commonly investigated
HDACs in the context of cognition (Society for the Study of Evolution., 1947). Class II

2

HDACs are larger and contain more regulatory domains. These HDACs are further
subdivided into class IIa HDACs (HDAC4, 5, 7, and 9) and class IIb HDACs (HDAC6, and
10), which are predominantly capable of migrating between the cytoplasm and nucleus,
and are expressed in a cell-specific manner (Morris & Monteggia, 2013). Class IV is
represented by HDAC11, which is also found within the nucleus and is expressed in the
brain primarily within oligodendrocytes (Gräff & Tsai, 2013; Singh et al., 2018)
There are four major classes of small-molecule HDACi that include: 1) carboxylic acids
(i.e., sodium butyrate, valproic acid), 2) hydroxamic acids (i.e., trichostatin A, SAHA), 3)
benzamides (i.e., MS-275), and 4) natural products (i.e., FK228) (Haggarty & Tsai, 2011).
The classes of small-molecule HDACis all vary in their selectivity towards the
aforementioned classes of HDACs. Sodium butyrate, valproic acid, MS-275, and FK228
are all selective towards inhibiting class I HDACs, whereas trichostatin A and SAHA inhibit
both class I and II HDACs (Yoshida et al., 1990; Furumai et al., 2002; Ryan et al., 2005;
Duvic et al., 2007; Kim & Bae, 2011). Only the first three classes of HDACi have been
studied in animal models of the context of learning and memory (Alarcón et al., 2004;
Korzus et al., 2004; Lattal et al., 2007; Levenson et al., 2004; Guan et al., 2009; Stefanko
et al., 2009). As such, the experiments in this thesis will use sodium butyrate (NaBu) as
our positive control because NaBu is capable of crossing the blood brain barrier when
administered i.p. and selectively inhibits class I HDACs.
Memory Formation Accompanies Increased Histone Acetylation
Although scientists have long studied how memories are formed, the
neurobiological nature of the memory trace remains a subject of intense inquiry. The
mysterious nature of memory formation stems from the fact that the proteins supporting
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the formation of long-term memories eventually turnover, which begs the question of how
memories can persist for years (Crick 1984; Roberson & Sweatt, 1999). The biochemical
blueprint for long-term memory is now considered to be regulated, in part, by experiencedependent changes to the epigenome (Zovkic et al., 2013; Marshall & Bredy, 2016). In
particular, histone acetylation is a molecular driver of successful long-term memory
formation (Federman et al., 2009). Seminal work demonstrated that long-term facilitation
in the sea slug, Aplysia californica, preferentially increases levels of H3 and H4
acetylation of the CAAT enhancer binding protein (C/EBP) promoter, whereas long-term
depression prevented H3 and H4 acetylation of C/EBP (Guan et al., 2002). These findings
were among the first to demonstrate that the opposing actions of histone acetylation and
deacetylation are a critical force underlying synaptic plasticity. This work led to another
seminal study conducted in male rats that demonstrated H3, but not H4, hippocampal
acetylation was increased 1h, but not 24h, after contextual fear conditioning, whereas
latent inhibition (another form of associative learning) preferentially increased
hippocampal H4, but not H3, acetylation (Levenson et al., 2004). This work not only
demonstrated that histone acetylation is associated with long-term memory formation in
male rats, but also raised questions about how different forms of learning elicit different
histone acetylation patterns in the brain. Since then, other work has demonstrated that
histone acetylation in the hippocampus is associated with memory enhancement in a
number of behavioral tasks including contextual fear conditioning in male rodents
(Chwang et al., 2007; Vecsey et al., 2007) and fear extinction in male rats (Lattal et al.,
2007; Stafford et al., 2012), as well as object recognition in male (Korzus et al., 2004;
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Fontán-Lozano et al., 2008) and ovariectomized female mice (Zhao et al., 2010; 2012;
Fortress et al., 2014).
Furthermore, other work has demonstrated that increases in histone acetylation
do not necessarily occur on a genome-wide level, but rather, targets the promoters of
numerous genes deemed critical for memory formation (Gräff & Tsai, 2013). For instance,
contextual fear conditioning in male rats has been shown to specifically increase H3
acetylation in the promoter IV region of the brain-derived neurotrophic factor (bdnf) gene
(Lubin et al., 2008), whereas behavioral tasks assessing fear extinction trigger increases
in H4 acetylation of promoter IV bdnf in the prefrontal cortex (Bredy & Barad, 2008). Work
from our lab has demonstrated that the memory enhancing effects of 17-estradiol, which
require H3 acetylation, specifically increase levels of H3 acetylation at bdnf promoters II
and IV in young and middle-aged ovariectomized female mice (Zhao et al., 2010; 2012;
Fortress et al., 2014).
Thus, histone acetylation is an epigenetic mechanism that is associated with
successful forms of long-term memory formation by acting in part as a transcriptional
activator for memory-promoting genes.
Targeting Histone Deacetylases To Assess Memory Formation
The data indicating that histone acetylation is involved in synaptic plasticity and
learning behavior led to questions about which specific HDAC isoforms are responsible
for long-term memory formation. In particular, the role of class I HDACs in modulating
learning and memory were of specific interest given recent evidence showing that class I
HDAC inhibitors (such as NaBu) could reinstate learning in mice with massive neuronal
loss (Fischer et al., 2007), and that class I HDACs were predominately expressed in areas
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responsible for memory formation itself (Broide et al., 2007). In a landmark study, Guan
et al. (2009) systematically assessed the involvement of HDAC1 and HDAC2 in
associative learning and synaptic plasticity by developing four different strains of mice
who either overexpressed (OE) or contained a knockout (KO) of HDAC1 or HDAC2. They
observed decreased H4K5 and H4K12 acetylation in HDAC2OE mice, a molecular
signature that was accompanied with reduced freezing during context- and tonedependent fear learning, as well as impaired spatial navigation in the Morris water maze,
both of which were behavioral impairments not observed in HDAC1OE mice. Conversely,
the authors observed that HDAC2KO mice exhibited reinstated H4K5 and H4K12
acetylation, as well as increased freezing during the context- and tone-dependent fear
learning tasks. Furthermore, HDAC2KO mice had increased H3 and H4 acetylation of
memory-promoting genes (i.e. Bdnf, Egr1, Fos, Creb) in the hippocampus, which was
accompanied by increased density of dendritic spines on CA1 pyramidal neurons (Guan
et al., 2009). Additionally, a subsequent study reported that focal HDAC3 deletions within
the mouse hippocampus resulted in spatial memory enhancement in an object location
task, an effect that was accompanied by increased acetylation of the immediate early
gene c-fos (McQuown et al., 2011a). Collectively, these studies demonstrated that
HDAC2 and HDAC3, but not HDAC1, are negative regulators of long-term memory
formation in mice. Perhaps more importantly, these studies highlight the enormous
therapeutic potential in bidirectionally modifying activity of individual HDACs to preserve
long-term memory formation.
Although overexpression, knockouts, and focal deletions of particular HDACs are
useful tools for examining the role of HDACs in learning and memory, their therapeutic
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utility in humans is limited because deletion of HDACs would have long-term effects on
other biological roles of HDACs outside of the central nervous system, including cell-cycle
progression, differentiation, and apoptosis (Ropero & Esteller, 2007). Although extant
HDACi compounds cannot discern amongst specific isoforms of HDACs, they have
nonetheless provided the field of behavioral neuroscience with useful insights into how
histone acetylation regulates spatial and object recognition memory in rodents. For
instance, systemic pre-training injection of NaBu facilitates the formation of long-term
object recognition memory in male mice (Stefanko et al., 2009b). Our lab has also
demonstrated that immediate post-training dorsal hippocampal infusion of HDACi
trichostatin A (TSA) enhances object recognition memory consolidation in ovariectomized
female mice (Zhao et al., 2010). Furthermore, pre-training dorsal hippocampal infusion of
TSA enhances long-term object placement memory in male mice (Hawk et al., 2011).
Together, these studies indicate that HDACi treatment can enhance long-term spatial and
object recognition memory.
Developing Selective HDACi to Treat Disorders of Cognition
The balance between histone acetylation and deacetylation goes awry in
neurodegenerative disease, such that cells start to overexpress HDACs, ultimately
reducing gene transcription (Saha & Pahan, 2006). Based on the promising
neuroprotective effects of non-selective HDACi (pan-HDACi) in animal models of
neurodegenerative disease, it was thought that these benefits would translate well the
clinical setting (Kazantsev & Thompson, 2008; Yang et al., 2017) A handful of studies
have assessed the efficacy of pan-HDACi compounds for ameliorating symptoms in
cognitive disorders, including Alzheimer’s disease (clinicaltrials.gov, NCT03056495),
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Huntington's disease (NCT00212316), and schizophrenia (NCT03010865). However, this
work has been largely unsuccessful because none of the trials resulted in the approval of
pan-HDACi for the treatment of neurodegenerative disease or cognitive disorders (Shukla
& Tekwani, 2020).
Our understanding of the shortcomings of pan-HDACi compounds (i.e., SAHA,
FK228, vorinostat) as treatment options for neurodegenerative disease has largely come
from studies assessing the efficacy of these same compounds in cancer patients.
Consensus in the field is that the non-selective nature of pan-HDACi compounds
contributes to the cytotoxicity and negative side effects (i.e., fatigue, nausea, dehydration,
reduced blood platelet count) observed in clinical trials (Hamze 2020). Additionally, panHDACi have poor blood-brain barrier permeability, which precludes their use in treating
disorders of the central nervous system (Hiranaka et al., 2018). Therefore, developing
isoform-selective HDACi that retain neuroprotective and memory-enhancing properties is
a challenging obstacle for researchers due to the high sequence similarity in both the
active site structure and catalytic mechanism of individual HDACs (Bieliauskas & Pflum,
2008).
Furthermore, developing HDACi that target particular HDACs is challenging
because HDAC proteins do not function as independent enzymes. HDACs are known to
form heterodimers and homodimers within different families of large multiprotein
repressor complexes (i.e., Sin3, NuRD, CoREST) (Delcuve & Davie, 2012). HDACs are
capable of repressing gene transcription only when they are bound to their larger corepressor complex and recruited to regulatory stretches of DNA by transcription factors
(i.e., p53, NF-kB, YY1). For example, HDAC1 and HDAC2 are known to dimerize with
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one another in all three types of repressor complexes such that the HDACs themselves
form heterodimers (HDAC1/2) or homodimers (HDAC1/1 or HDAC2/2) to carry out their
repressive effects on transcription (De Ruijter et al., 2003; Yang & Seto, 2008). Therefore,
it is challenging to develop isoform-selective HDACi that target a single HDAC without
affecting the activity of other HDACs.
Pan-HDACi are known to target non-histone proteins that can alter transcriptional
activity in cells (Delcuve & Davie, 2012). A majority of the behavioral work utilizing panHDACi has suggested that the beneficial effects of HDACi treatment are a direct
consequence of inhibiting HDACs. However, HDACis can also indirectly increase gene
expression by preventing the deacetylation of other non-histone proteins, such as
transcription factors and nuclear transport proteins (Delcuve & Davie, 2012; Seto &
Yoshida, 2014). Although challenging, developing isoform-selective HDACi would be a
major step in reducing unwanted side effects of pan-HDACi that alter the activity of
HDACs responsible for cell-cycle progression, differentiation, and apoptosis (Ropero &
Esteller, 2007). Therefore, there is a clear need to use isoform-selective HDACi in
behavioral studies assessing long-term memory formation because these would reduce
the sheer volume of possible non-histone targets and provide a more detailed view of the
role of individual HDACs in learning and memory.
Design and Efficacy of MJM-1 In Vitro
Development of small-molecule HDACi typically follows a pharmacophore model
that contains a cap, linker, and zinc binding group (Figure 2). The cap and linker groups
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Figure 2. Scaffold of MJM-1. The composition of MJM-1 is modeled after
the scaffold of the FDA-approved HDACi FK228.

ion at the bottom of the HDAC pocket in class I, II, and IV HDACs and is considered to
be a region that contributes to the overall activity of HDACi (Manal et al., 2016; Zhang et
al., 2018). MJM-1 contains a noticeably smaller polar cap group (Figure 2), which gives
MJM-1 the advantage of being more soluble and being permeable to the blood-brain
barrier. The linker region of MJM-1 contains a six-carbon chain, approximately 11 Å,
which is the reported length of all class I HDAC pockets (Wang 2009). Lastly, MJM-1
contains a disulfide bond as its zinc binding group, which is known to have a strong affinity
for the active site in all zinc-dependent HDACs (Manal et al., 2016). Thus, the chemical
and structural properties of MJM-1 address a major limitation of most HDACi in that it is
highly soluble and capable of crossing the blood brain barrier, indicating that the current
scaffold of MJM-1 is an ideal compound for observing effects on long-term memory
formation.
Our collaborators were first interested in examining the extent to which MJM-1
modifies histone acetylation in vitro relative to a potent dose of HDACi FK228. They first
treated DU145 cells with DMSO, 10 nM FK228, or one of three separate doses of MJM1 (25, 50, or 100 µM) for 24 h before immunolabeling for acetyl-H3 (Lys 9/Lys 14). These
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cells were chosen because they overexpress class I HDACs that inhibit the expression of
tumor suppressor genes that ultimately permit prostate cancer cell proliferation and
invasion (Weichert et al., 2008). Their findings indicate that MJM-1 dose-dependently
increases acetyl-H3 (Lys 9/Lys 14) relative to DMSO-treated controls (Appendix Figure
1A-E). The observed levels of histone acetylation after MJM-1 treatment were
qualitatively lower than those after treatment of FK228, suggesting that MJM-1 has a
more favorable safety profile than FK228. They next determined the extent to which MJM1 alters activity of recombinant purified HDACs relative to FK228. They demonstrated that
despite being less potent than FK228, MJM-1 similarly inhibited both class I (HDAC1, 2,
3, and 8) and class IIb HDACs (HDAC6) (Appendix Figure 1F).
We were then interested in examining the extent to which two different doses of
MJM-1 cross the blood brain barrier and be detected in the DH following a single i.p.
injection. Male mice received an i.p. injection of either 20 or 40 mg/kg MJM-1, and DH
tissue collected 10 or 30 min later (Appendix Figure 2A). Here, utilizing mass
spectrometry (Shimadzu LCMS-8040), our group demonstrated that 20 mg/kg MJM-1 can
be detected in the DH 10 min following i.p. administration (Appendix Figure 2B), whereas
40 mg/g MJM-1 can be detected at both 10 and 30 min (Appendix Figure C-D). These
data suggest that MJM-1 penetrates the blood brain barrier and diffuses rapidly into the
hippocampus after i.p. administration. Given that both 20 and 40 mg/g doses were
detected in the brain, the present study examined the effects of 20, 30, and 40 mg/g MJM1 on memory consolidation.
As such, the goals of this thesis were to determine the extent to which post-training
administration of MJM-1 enhances spatial and object recognition memory and alters
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hippocampal histone acetylation and bdnf gene expression in male mice. The preliminary
data gathered by our collaborators collectively suggest that MJM-1 increases H3
acetylation in vitro, inhibits class I and IIb HDACs, and quickly penetrates the blood-brain
barrier into the mouse hippocampus following i.p. administration. These findings helped
form our hypotheses that MJM-1 would enhance spatial and object recognition memory
consolidation in part by increasing global hippocampal histone acetylation or bdnf
expression levels. Our results indicate that MJM-1 enhances spatial, but not object
recognition, memory consolidation in male mice. Surprisingly, however, we observed no
treatment effects of MJM-1 on hippocampal histone acetylation or bdnf expression
patterns. Although the molecular mechanisms underlying MJM-1’s beneficial effect on
spatial memory consolidation remain unclear at the present time, this work provides a
useful framework for understanding how to better develop small-molecule HDACis that
can potentially be used to improve memory decline.

METHODS
Subjects
Male C57BL/6 mice were obtained from Taconic Biosciences (Germantown, NY)
at 10 weeks of age and housed individually in shoebox cages in a room (22-23°C) with a
12/12-h light-dark cycle. Food and water were provided ad libitum. Mice were handled 30
s/day for 3 days before behavioral testing. All procedures were conducted from 10:00 to
17:00 h in a quiet room, and experimenters conducting behavioral testing were blind to
the treatment each mouse received. All procedures were approved by the University of
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Wisconsin-Milwaukee Institutional Animal Care and Use Committee and are consistent
with the National Institutes of Health Guide for the Care and Use of Animals.
General Experimental Design
The purpose of this study was to determine the extent to which MJM-1 can
enhance memory consolidation and hippocampal histone acetylation and bdnf expression
in male mice. Four separate cohorts were used in total for the behavioral and molecular
experiments (Table 1). Cohorts 1 and 2 (n=60 each; 12/treatment) were used for OP and
OR behavioral testing, where mice received an immediate post-training i.p. injection of
one of five possible treatments. Negative control mice received injections of 100%
dimethyl sulfoxide (DMSO). Positive control mice received sodium butyrate (0.6 g/kg
NaBu), an HDACi that has been previously shown to enhance object recognition memory
in male mice (Stefanko et al., 2009). Experimental mice received one of three doses of
MJM-1 (20, 30, or 40 mg/kg) that our group shown to be present in the DH following i.p.
administration (Appendix Figure 2). Upon completion of behavioral testing, all mice
received a final i.p. injection of DMSO, NaBu, or one of three doses of MJM-1 (20, 30, 40
mg/kg), and DH tissue was collected 60 min later to assay histone acetylation alterations.
To determine the extent to which histone acetylation was altered by post-training
MJM-1 treatment, Cohort 3 (n=36; 12/treatment) underwent object training and received
an immediate post-training i.p. injection of DMSO, NaBu, or 40 mg/kg MJM-1, and DH
was collected 30 min later to assay histone acetylation alterations.
To determine the extent to which MJM-1 treatment modifies hippocampal
expression levels of bdnf exons I and IV, Cohort 4 (n=24; 8/treatment) received a single
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i.p. injection of DMSO, NaBu, or 40 mg/kg MJM-1, and DH tissue was collected 60 min
later to assay bdnf expression.
Table 1: General Experimental Design.
Cohort
1
2
3
4

Treatment Received
DMSO, NaBu, or MJM1 (20, 30, 40 mg/kg)
DMSO, NaBu, or MJM1 (20, 30, 40 mg/kg)
DMSO, NaBu, MJM-1
(40 mg/kg)
DMSO, NaBu, MJM-1
(40 mg/kg)

Behavior
OP and OR
OP and OR
Object
Training

Tissue
Collection
60 min following
final i.p.
60 min following
final i.p.
30 min following
post-training i.p.
60 min following
single i.p.

-

Assays
OR/OP; WB DH histone
acetylation
OR/OP; WB DH histone
acetylation
WB DH histone acetylation
qPCR bdnf exons I and IV

Drugs and Injections
All drugs were prepared the day of use and administered by a single i.p. injection
at a volume of 5 m/kg. NaBu was dissolved in sterile saline to a concentration of 0.6 g/kg
(Stefanko et al., 2009). Our group’s novel brain-penetrant HDACi compound, MJM-1, was
dissolved in 100% DMSO to a concentration of 40 mg/kg, and then serially diluted to
concentrations of 30 and 20 mg/kg. These doses were chosen because our data indicate
that a 40 mg/kg dose of MJM-1 can be detected in the DH of male C57BL/6 mice by
Shimadzu LCMS-8040 mass spectrometry both 10 and 30 min following a single i.p.
injection (Appendix Figure 2C-D). Our data also suggest that a 20 mg/g dose of MJM-1
can be detected in the DH 10 min following a single i.p. injection (Appendix Figure 2B).
Behavioral Tasks
The memory-enhancing effects of MJM-1 were examined in Cohorts 1 and 2
through use of object placement (OP) and object recognition (OR) behavior paradigms
which assess spatial and object recognition memory, respectively (Boulware et al., 2013;
Fernandez et al., 2008; Tuscher et al., 2016). Cohort 3 mice were first assigned to either
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Homecage or Trained groups and received the same handling, habituation, and object
training procedure described below without behavioral testing.
OP

and

OR

were

conducted in a white open field
box (width, 60 cm; length, 60 cm;
height, 47 cm). Prior to behavioral
training, mice were handled for 30
s/day for 3 days. On the second
day of handling, a single Lego
Duplo block was placed in the
home cage to acclimate mice to
objects. Following handling, mice
underwent a single habituation
session for 5 min/day for 2 days.
During habituation, mice were
allowed to move about freely in
the apparatus without objects

Figure 3. Overview of behavioral testing protocols. A) In
object placement, mice accumulate 30 s exploring 2 identical
objects in an open arena. Mice then mice receive a post-training
i.p. injection of DMSO, NaBu, or MJM-1 (20, 30, or 40 mg/kg).
Retention is tested 24h later by moving one training object to a
lower corner of the box. Mice who remember the familiar object
spend more time than chance (15 s) exploring the moved object.
B) Object recognition uses the same apparatus and general
procedure, except during testing, mice are presented with a
novel object. Testing is conducted 48 h after i.p. injection of
compounds because OR memory persists longer than OP
memory.

present. Following habituation, mice underwent OP and OR training, during which mice
were given up to 20 min to accumulate 30 s exploring two identical objects placed in the
upper right- and left-hand corners of the box. Experimenters manually scored (in real
time) the amount of object exploration using ANYmaze tracking software (Stoelting).
Object exploration was defined as when the mouse’s nose and/or front paws were
directed towards and/or touching the objects. Different objects were used for OP and OR,
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and all objects used were counterbalanced across mice to account for any potential
effects of object preference. Immediately following training, mice received an i.p. injection
of one of the compounds described above. All treatments in OP and OR were
administered immediately post-training to pinpoint effects of MJM-1 on the consolidation
phase of spatial and object recognition memory formation, respectively. If mice did not
accumulate 30 s of exploration time during training, then were then retrained 4-7 days
later with different objects. OP and OR were tested 24- and 48-hours post-training,
respectively (Figure 3A-B). These time points were chosen based on previous evidence
that vehicle-treated gonadally-intact male mice no longer remember the location or
identity of the objects at these time points (Koss et al., 2018). Similarly, gonadally-intact
male mice can remember object identity 24 hr after OR training (Frick & Gresack, 2003).
OP testing consisted of moving the least-explored training object to either the lower rightor left-hand corner of the box (Figure 3A). OR testing consisted of replacing the leastexplored training object with a novel object that mice had not previously encountered
before (Figure 3B). Mice were given 20 min to accumulate 30 s of exploration time during
OP and OR testing. Chance is designated at 15 s because this value represents equal
exploration of both objects (Frick & Gresack, 2003). If they did not accumulate 30 s of
exploration time then the mouse was given up to three separate chances to successfully
complete the task. All mice were given at least one week between bouts of testing to
ensure that any acute effects of previous drug injections dissipated before the next
treatment.
Tissue Collection
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At the conclusion of behavioral testing, Cohorts 1 and 2 received a final i.p.
injection of DMSO, NaBu, or one of three doses of MJM-1 (20, 30, or 40 mg/kg), and DH
tissue was collected on 60 min later on wet ice and immediately frozen at -80°C. The 60
min timepoint was chosen because work from our lab assessing object recognition
memory in ovariectomized mice has demonstrated that DH infusion of non-selective
HDACi TSA increases H3 acetylation in the DH at 30 min (Zhao et al., 2010). We
predicted that any histone acetylation changes from i.p. administration of MJM-1 would
take longer than an intrahippocampal infusion, and as such, were expected to be detected
in the DH by 60 min. Cohort 3 received a post-training i.p. injection of DMSO, NaBu, or
40 mg/kg MJM-1, and DH tissue was collected 30 min later on wet ice and immediately
frozen at -80°C. The 30 min timepoint was chosen because previous studies found that
administering a single i.p. injection of a 1.2 g/kg dose of NaBu following training
significantly altered H3 and H4 acetylation levels in the DH at 30 min (Fischer et al., 2007;
Gundersen & Blendy, 2009a; Takuma et al., 2014). Cohort 4 received a single i.p.
injection of DMSO, NaBu, or 40 mg/kg MJM-1, and DH tissue was collected 60 min later.
Samples were placed in RNAlater solution (ThermoFisher Scientific), and stored at 4°C
overnight, and then transferred to -20°C for storage.
Histone Extractions
All tissue samples were individually processed using the EpiQuik Total Histone
Extraction Kit (EpiGentek, Farmingdale, NY) to maximally isolate histone proteins and
preserve post-translational modifications. Briefly, tissue samples were homogenized in
1X pre-lysis buffer with a pellet-tissue grinder (Kimble) for 45 s and then centrifuged at
10,000 rpm for 1 min at 4°C. The remaining tissue pellet was resuspended in 3 volumes
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of lysis buffer, incubated on ice for 30 min, and centrifuged at 12,000 rpm for 5 min at
4°C. Following centrifugation, the supernatant containing acid soluble histone proteins
was transferred to a new 1.5 mL tube and balance-dithiothreitol (DTT) buffer (0.3
volumes) were added to the histone fraction. The protein concentration of the eluted
histone fraction was then estimated using a Bradford protein assay (Bio-Rad, Hercules,
CA) using bovine serum albumin (BSA) as a standard. Samples were stored in -80°C until
future preparation of Western blot aliquots.
Western Blotting
Histone fractionated samples were normalized to 2 µg/µl by adding corresponding
amount of sample buffer, lysis buffer, and homogenate in preparation for Western blotting.
Samples were boiled for 5 min to denature proteins. Proteins were electrophoresed in 10
µl aliquots on 4-15% Tris-HCl polyacrylamide gels (Bio-Rad) and transferred to PVDF
Midi membranes using a TransBlot Turbo transfer system (Bio-Rad). Membranes were
blocked in 5% dried non-fat milk/TTBS and incubated overnight at 4°C with the following
primary antibodies: acetyl-H2B (Lys 12), acetyl-H3 (Pan), acetyl-H3 (Lys 14), acetyl-H3
(Lys 9, Lys 14), and acetyl-H4 (Lys 12) (1:1000, Cell Signaling Technology). These
acetylation sites were chosen to include all core histone proteins across a range of
different lysine sites to assess which, if any, sites MJM-1 may preferentially acetylate. In
particular, modifications to these lysine sites have been previously shown responsible for
memory formation and synaptic plasticity (Alarcón et al., 2004; Levenson et al., 2004;
Guan et al., 2009; Zhao et al., 2010; Valor et al., 2011). Blots were incubated the next
day for 1 h at room temperature with rabbit HRP-conjugated secondary antibody (antirabbit HRP, 1:5000, Cell Signaling Technology). Membranes were then developed using
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Clarity Max chemiluminescent substrate (Bio-Rad), and imaged using a ChemiDoc MP
gel imager (Bio-Rad). Blots were then stripped with 0.2 M NaOH and incubated with the
following antibodies for protein normalization: total-H2B (1:1000, Cell Signaling
Technology), total-H3 (1:1000, Cell Signaling Technology), total-H4 (1:2000, Cell
Signaling Technology). Dilutions of the aforementioned antibodies are based on
previously published work from our lab (Zhao et al., 2012; Fortress et al., 2014).
Densitometry analysis were conducted using Image Lab software (Bio-Rad, Image Lab
version 6.0.1) and data are represented as percent of immunoreactivity relative to vehicle
controls.
Real-Time Quantitative PCR
RNA was prepared and quantified as described previously (Zhao et al., 2010;
Fortress et al., 2014; Gross et al., 2021). Briefly, RNA was extracted using the Qiagen
RNeasy Mini kit (Qiagen) following the manufacturer’s instructions. Total RNA
concentration was determined by reading absorbance at 260 and 280 nm using an Agilent
Epoch Microplate Spectrophotometer (BioTek, Winooski, VT) and cDNA samples were
prepared from 1 µg of extracted RNA using a Bio-Rad iScript cDNA Synthesis kit (BioRad). Real-time quantitative PCR (RT-qPCR) was performed using SYBR Green Master
Mix (Bio-Rad) on an Eppendorf Realplex 2 PCR System (Eppendorf). Primers for bdnf I
and IV transcripts (Table 2) were obtained from Integrated DNA Technologies (Coralville,
IA). Predesigned and optimized RT2 qPCR Primer Assays (Qiagen) were used for
analysis of Gapdh (#PPM02946E) as an expression control. RT-qPCR reactions were
run at 95˚C for 10 min and 40 cycles of 95˚C for 15 s, followed by 60˚C for 60 s, 95˚C for
15 s and 60˚C for 15 s, and then held at 95˚C for 15 s. All samples were run in triplicate
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and normalized to corresponding GAPDH values, and the ΔΔCT method was used to
calculate relative expression of each gene of interest (Zhao et al., 2010; Fortress et al.,
2014; Gross et al., 2021).
Table 2: Primers Used for qPCR Analysis of bdnf Exons I and IV
Gene names
bdnf Exon I
bdnf Exon IV

Primer sequences
F: 5' GGA AAC GTC TCT CTC AGA ATG A -3’
R: 5' TCA TCC ACC TTG GCG ATT AC -3’
F: 5' CTC AAG CGC TGC GAG TAT TA -3’
R: 5' AGT CCT TGG CCG ATA TG -3’

Statistical Analyses
Statistical analyses were conducted using GraphPad Prism 8 (La Jolla, CA). All
data were analyzed for outliers, defined by ± 2 standard deviations from the mean, which
were removed prior to additional analysis. For each behavioral experiment, separate onesample t-tests were performed for each group to determine if the time spent with the novel
object differed from chance (15 s; Boulware et al., 2013; Frick & Gresack, 2003; Tuscher
et al., 2016). To assess between-group treatment effects within each behavioral task,
one-way analyses of variance (ANOVAs) were conducted followed by Fisher’s LSD post
hoc tests. For Western blotting analyses, one-way ANOVAs were conducted followed by
Tukey’s multiple comparison post hoc tests for between-group comparisons. For qPCR
analyses, the ΔΔCT method was used to obtain normalized values to vehicle-treated
mice. One-way ANOVAs were conducted followed by Tukey’s multiple comparison post
hoc tests for between-group comparisons. Significance was determined as p ≤ 0.05.
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RESULTS
MJM-1 Enhances Spatial, but not Object Recognition, Memory Consolidation
We were first interested in assessing the extent to which MJM-1 can enhance
memory consolidation in male mice. As described in the Methods Section, the OP and
OR tasks were used to assess spatial and object recognition memory consolidation,
respectively. Briefly, each task consists of a training phase in which mice must
accumulate 30 s exploring two identical objects in an open field (Figure 3A-B).
Immediately after training, mice were injected i.p. with DMSO, NaBu, or one of three
doses of MJM-1 (20, 30, 40 mg/kg).
Multiple doses of MJM-1 enhanced spatial memory consolidation (Figure 4A).
Although a one-way ANOVA did not indicate significant between-group differences (F(4,
78)

= 1.134; p = 0.3467), one-sample t-tests that assess memory within each group

revealed a differential pattern of spatial memory consolidation among the groups. Mice
receiving DMSO did not spend significantly more time with the moved object than the
chance value of 15 s (t(16) = 0.6857, p > 0.05; n=17), suggesting that this group exhibited
impaired memory for object location. In contrast, mice receiving NaBu spent significantly
more time than chance with the moved object (t(14) = 2.265, p = 0.0399; n=15), indicating
enhanced memory for object location. Similarly, mice receiving 20 mg/kg MJM-1 (t(16) =
2.244, p = 0.0393; n=17) or 40 mg/kg MJM-1 (t(15) = 5.248, p < 0.0001; n=16) also spent
significantly more time with the moved object than chance, indicating that these two doses
of MJM-1 enhanced spatial memory consolidation. Although not quite statistically
significant, mice receiving 30 mg/kg MJM-1 also tended to spend more time than chance
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with the moved object (t(17) = 2.054, p = 0.0556; n=18). These results suggest that acute
i.p. administration of MJM-1 can enhance spatial memory consolidation in male mice.
In contrast to its effects on spatial memory, MJM-1 did not influence object
recognition memory consolidation (Figure 4B). One-sample t-tests indicated that mice
receiving vehicle did not spend significantly more time than chance with the novel object
(t(12) = 1.533, p > 0.05; n=13). Although mice receiving NaBu spent significantly more
time than chance with the novel object, (t(14) = 3.915, p = 0.0016; n=15), those receiving
the 20, 30 or 40 mg/kg MJM-1 did not (ts(14-15) = 0.6089, 0.3235, and 1.747,
respectively, p > 0.05; n=15-16). The main effect of treatment was significant (F(4, 70) =
6.027; p = 0.0003), an effect driven by the fact that the NaBu-treated group differed
significantly from every other treatment group (NaBu vs. Veh: p = 0.0002; NaBu vs. 20: p
= 0.0077; NaBu vs. 30: p = 0.0013; NaBu vs. 40: p < 0.0001). Taken together, these
results indicate MJM-1 can enhance spatial, but not object recognition, memory
consolidation to a similar extent as the known memory-enhancing HDAC inhibitor NaBu.
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A

B

Figure 4. Post-training i.p. administration of MJM-1 enhances spatial, but not object recognition,
memory in male mice. A) Male mice receiving an i.p. injection of the HDACi sodium butyrate (NaBu), or
20 or 40 mg/kg of MJM-1 spent significantly more time than chance (dashed line at 15 sec, *p < 0.05, ****p
< 0.0001) with the moved object 24 h after training (n=15-18/group). Although not statistically significant,
mice receiving the 30 mg/kg dose of MJM-1 displayed a trend towards spending more time than chance
with the moved object (#p = 0.0556). B) Only mice receiving NaBu treatment spent significantly more time
than chance with the novel object 48 hr after training (**p < 0.01). Mice treated with NaBu also spent
significantly more time with the novel object than every other treatment group (n=13-15/group). Bars
represent the mean ± (SEM).

MJM-1 Treatment Did Not Increase Hippocampal Histone Acetylation
We next wanted to determine the extent to which the memory enhancing doses of
MJM-1 alter hippocampal histone acetylation. The mice used for OP and OR testing were
given two weeks before they received a final i.p. injection of DMSO, NaBu, or MJM-1 (20,
30, or 40 mg/kg), and the DH was collected 60 min later (Figure 6A). We first verified that
we achieved sufficient separation of histone and cytoplasmic fractions and that the
histone fraction contained detectable amounts of histone protein that could be assayed
via Western blot (Figure 5). Despite observing excellent separation, there was no
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significant main effect of treatment in the DH for altering histone acetylation for the sites
acetyl-H2B (Lys 12) (F(4, 56) = 0.7194, p = 0.5823, Figure 6B), acetyl-H3 (Pan) (F(4, 55) =
1.094, p = 0.3686, Figure 6C), acetyl-H3 (Lys 14) (F(4, 56) = 0.2665, p = 0.8983, Figure
6D), acetyl-H3 (Lys 9, Lys 14) (F(4, 55) = 1.387, p = 0.2504, Figure 6E), or acetyl-H4 (Lys
12) (F(4, 55) = 1.724, p = 0.1579, Figure 6F).
The lack of an effect for MJM-1 in the DH was surprising considering our group
found a dose-dependent increase in acetyl-H3 (Lys 9/Lys 14) immunofluorescence levels
in DU145 tumor cells relative to DMSO-treated cells (Appendix Figure 1) and because we
demonstrated that MJM-1 localizes to DH following systemic administration (Appendix
Figure 2). Moreover, the lack of an effect for NaBu is particularly surprising because this
compound is widely reported to increase bulk histone acetylation and because we found
that NaBu enhances spatial and object recognition memory consolidation. These data
alone suggest that a single i.p. injection of NaBu or MJM-1 does not alter global levels of
histone acetylation 60 min later within the DH.

Figure 5. Separation of histone and cytoplasmic fractions following histone extraction protocol. DH
tissue was homogenized and fractionated following the manufacturer’s protocol for EpiQuik Total Histone
Extraction Kit, and both fractions were prepared for Western blot and probed for acetyl-H3 (Lys 14). The
histone fraction contains acetyl-H3 (Lys 14) protein, whereas the cytoplasmic fraction does not.
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Figure 6. MJM-1 treatment did not alter histone acetylation levels in the dorsal hippocampus. A)
Schematic of tissue collection procedure. Two weeks after completion of behavioral training, mice received
a final i.p. injection of 100% DMSO, 0.6 g/kg NaBu, or one of three doses of MJM-1 (20, 30, or 40 mg/kg)
(n=12-13/group). DH tissue was collected 60 min later for Western blot analysis of B) acetyl-H2B (Lys 12),
C) acetyl-H3 (Pan), D) acetyl-H3 (Lys 14), E) acetyl-H3 (Lys 9/Lys 14), and F) acetyl-H4 (Lys 12)
modifications. Error bars represent mean  SEM. All p > 0.05.
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Post-Training MJM-1 Treatment Did Not Increase Hippocampal Histone Acetylation
Although HDACi have been used to enhance memory formation and rescue
cognitive impairments, it remains unclear how they are able to have targeted effects on
histone acetylation in brain regions that support cognition when administered
systemically. It is thought that HDACi are capable of enhancing memory formation
because they are administered around the time of learning, where task-relevant stimuli
are already promoting expression of genes relevant to synaptic plasticity (Gräff et al.,
2014). As such, we next sought to determine whether the lack of an effect on histone
acetylation alterations in the DH for our NaBu- and MJM-1-treated mice could be
explained by the following possibilities: that 1) we missed the timepoint in which these
transient histone acetylation alterations occur, or 2) our behaviorally effective doses of
NaBu and MJM-1, when administered alone, were not sufficient to drive global
hippocampal histone acetylation changes without learning involved (Stafford et al., 2012;
Raybuck et al., 2013).
We hypothesized that relative to Homecage controls, object training would
increase H3 or H4 acetylation levels, whereas mice who receive a post-training i.p.
injection of 0.6 g/kg NaBu or 40 mg/kg MJM-1 would have potentiated histone alterations
relative to both Homecage and DMSO-trained mice. However, we found that there was
no significant main effect of treatment for levels of acetyl-H2B (Lys 12) (F(3, 41) = 1.041, p
= 0.3844, Figure 7B), acetyl-H3 (Pan) (F(3, 41) = 0.2735, p = 0.8442, Figure74C), acetylH3 (Lys 14) (F(3, 41) = 0.4276, p = 0.7343, Figure 7D), acetyl-H3 (Lys 9/Lys 14) (F(3, 41) =
1.140, p = 0.3441, Figure 7E), or acetyl-H4 (Lys 12) (F(3, 41) = 0.3220, p = 0.8094, Figure
7F).
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Figure 7. Post-training i.p. administration of MJM-1 did not alter histone acetylation levels in the
dorsal hippocampus. A) Schematic of object training, post-training injection, and tissue collection
schedule. Following successful completion of training, mice were given an immediate post-training i.p.
injection of 100% DMSO, 0.6 g/kg NaBu, or 40 mg/kg MJM-1 (n=11-12/group). Homecage controls were
sacrificed in a counterbalanced fashion. DH tissue was collected 30 min later and samples were prepared
for Western blot analysis of B) acetyl-H2B (Lys 12), C) acetyl-H3 (Pan), D) acetyl-H3 (Lys 14), E) acetylH3 (Lys 9/Lys 14), and F) acetyl-H4 (Lys 12) modifications. Error bars represent mean  SEM. All p > 0.05.
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MJM-1 Treatment Did Not Increase Hippocampal bdnf Expression
We finally examined the extent to which the behaviorally effective doses of NaBu
and MJM-1 might alter expression of bdnf. Although our data suggest that NaBu and
MJM-1 do not enhance memory formation by altering hippocampal histone acetylation
when administered alone or following object training, we wanted to examine the possibility
that these compounds enhance memory by promoting the transcription of genes that
support synaptic plasticity. As such, we chose to examine bdnf because this neurotrophic
factor has been widely demonstrated to be critical for enhancing synaptic plasticity by
inducing structural and functional changes at synapses (Lu 2003; Leal et al., 2015;
Miranda et al., 2019). Previous work in male mice demonstrated that a single i.p. injection
of 1.2 g/kg NaBu immediately following object training increased mRNA expression levels
of bdnf exons I and IV relative to vehicle-trained controls in the hippocampus collected 60
min following object testing (Intlekofer et al., 2013). As such, we hypothesized that the
memory enhancing effects of NaBu and MJM-1 could arise in part by increasing
hippocampal expression of bdnf exons I and IV relative to DMSO-treated controls.
A new cohort of behaviorally naïve male mice received a single i.p. injection of
DMSO, NaBu, or 40 mg/kg MJM-1. DH tissue was collected 60 min later and stored in
RNAlater solution prior to RNA extraction and qPCR analysis of bdnf exon I and IV
transcripts (Figure 8A). A significant main effect of treatment was found for bdnf exon I
expression (F(2, 20) = 5.249, p = 0.0147, Figure 8B), such that levels of bdnf exon I were
significantly higher among NaBu-treated mice relative to MJM-1 treated mice (p < 0.05).
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However, there was no significant main effect of treatment found for bdnf exon IV
expression (F(2, 21) = 0.6951, p = 0.5101, Figure 8C).

Figure 8. MJM-1 treatment did not alter expression of bdnf exons I or IV in the dorsal hippocampus. A)
Schematic of injection and tissue collection procedure. Behaviorally naïve mice were given a single i.p. injection
of either 100% DMSO, 0.6 g/kg NaBu, or 40 mg/kg MJM-1 and total RNA was extracted for analysis of bdnf exons
I and IV were assessed 60 min later in the DH (n=7-8/group). B) MJM-1 treatment did not alter bdnf exon I
expression levels (p > 0.05). However, mice injected with 0.6 g/kg NaBu had increased bdnf exon I expression
relative to MJM-1 treated mice (*p < 0.05). C) None of the treatments altered bdnf exon IV expression levels (p >
0.05). Error bars represent mean  SEM.

DISCUSSION
Effects on Spatial and Object Recognition Memory Consolidation
We first demonstrated that MJM-1 can enhance spatial memory consolidation in
male mice. A single post-training i.p. injection of 20 or 40 mg/kg MJM-1, and to a lesser
extent 30 mg/kg MJM-1, enhanced spatial memory consolidation in the object placement
task. These findings also indicate that MJM-1 enhances spatial memory consolidation in
a similar manner to the established HDACi NaBu. The spatial memory enhancing effects
of MJM-1 are consistent with a number of previously published studies utilizing extant
HDACi in object placement tasks. For instance, post-training i.p. administration of NaBu
has been previously shown to enhance spatial memory in male mice using a comparable
object placement task (Haettig et al., 2011). Similarly, post-training infusion of NaBu or
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other HDACi, including MS-275 and TSA, directly into the dorsal hippocampus enhances
object placement memory consolidation in male mice (Hawk et al., 2011; Roozendaal et
al., 2010). As such, the ability of MJM-1 to facilitate spatial memory formation is consistent
with those of other well established HDACi.
In contrast, our data also indicate that MJM-1 does not enhance object recognition
memory consolidation. The lack of an effect on object recognition memory is inconsistent
with other studies in which post-training i.p. injection of NaBu given to young or aged male
rodents or dorsal hippocampal infusion of TSA given to young ovariectomized female
mice enhances object recognition memory consolidation (Stefanko, et al., 2009; Zhao et
al., 2010; Haettig et al., 2011; Reolon et al., 2011). The reasons for this discrepancy are
unclear at the present time. The object placement and recognition tasks are frequently
used in the field of learning and memory because they are non-aversive, one-trial learning
tasks that are amenable to repeated use of pharmacological interventions (Tuscher et al.,
2015). However, the distinct molecular mechanisms that support the formation of spatial
and object recognition memories remain unclear, let alone how HDACi interact within the
existing molecular framework to enhance one form of learning over another.
The inconsistent effects of MJM-1 on spatial vs. recognition memory may reflect
distinct contributions of individual HDACs that support memory formation in a taskspecific manner. For instance, mice that overexpress HDAC2, but not HDAC1, exhibited
impaired spatial memory formation (Guan et al., 2009), whereas focal deletion of HDAC3
in the dorsal hippocampus enhanced spatial, but not object recognition, memory in male
mice (McQuown et al., 2011). Therefore, MJM-1 may preferentially influence spatial
memory by partially inhibiting the activity of class I HDAC2 and HDAC3. Alternatively,
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differential regulation by MJM-1 of the histone acetyltransferase transcription factor/coactivator complex CREB (cAMP response element binding protein) binding protein (CBP)
may play a role, as post-training i.p. injection of NaBu enhances both spatial and object
recognition memory in wild-type mice, but only facilitates object recognition in CBP mutant
mice (Haettig et al., 2011). Thus, spatial and object recognition memory may differ in their
requirement for interactions with CREB:CBP proteins.
Finally, the differential effects of MJM-1 on these two types of memory may relate
to the brain circuitry that mediates them. Whereas spatial memory in rodents
predominately relies on the hippocampus (Broadbent et al., 2004), object recognition
memory is involving the hippocampus, insular cortex, and multiple regions of the temporal
lobe (Hammond et al., 2004; Wilson et al., 2013). Interestingly, NaBu enhanced object
recognition memory consolidation when it was infused post-training into the insular cortex,
but not hippocampus, of male rats (Roozendaal et al., 2010). Although our mass
spectrometry analyses indicated MJM-1 penetration into the hippocampus, it remains
unclear whether MJM-1 localizes to and/or activates other brain regions that are relevant
for object recognition memory formation.
Effect of Isolated Treatment on Hippocampal Histone Acetylation
We next wanted to examine the extent to which MJM-1 alters hippocampal histone
acetylation relative to NaBu. We expected to see that MJM-1 treatment alone would
increase histone acetylation in the DH at sites on H2B, H3, and H4 proteins, which have
been previously shown to be altered by long-term memory formation and synaptic
plasticity (Peixoto & Abel, 2012). However, we found that the 20, 30, and 40 mg/kg doses
of MJM-1 did not alter global H2B, H3, or H4 acetylation levels in DH tissue assayed 60
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min following injection. These findings are surprising considering multiple doses of MJM1 enhanced spatial memory consolidation in the object placement task. Moreover, they
are inconsistent with our immunofluorescence data demonstrating there is a dosedependent effect of MJM-1 on H3 acetylation, such that higher doses of MJM-1 increase
overall H3 (Lys 9, 14) immunofluorescence relative to DMSO-treated cells. However, it is
possible that MJM-1 increases global histone acetylation in this context because the
DU145 cell lines naturally overexpress HDACs (Abbas & Gupta, 2008). Nonetheless,
these findings suggest that MJM-1 treatment alone is not sufficient to alter hippocampal
histone acetylation and likely acts through a different mechanism to enhance spatial
memory formation in mice.
We also did not find any treatment effects of NaBu on H2B, H3, or H4 acetylation.
We were surprised to find that 0.6 g/kg dose of NaBu did not alter histone acetylation
when this dose was sufficient to enhance both spatial and object recognition memory
consolidation in our object placement and recognition tasks. Although numerous studies
have examined the beneficial effects of NaBu on long-term memory formation and in
ameliorating behavioral deficits caused by neurodegenerative disease, very few of those
studies examined the degree to which a single systemic dose of NaBu alters histone
acetylation levels in the brain. For example, i.p. administration of 0.6 g/kg NaBu was
previously found to enhance object recognition memory consolidation (Stefanko et al.,
2009), but this group did not examine the extent to which this dose enhances object
recognition memory by increasing hippocampal histone acetylation. There have been no
studies that directly examined the extent to which a single i.p. injection of 0.6 g/kg NaBu
modifies hippocampal histone acetylation levels 60 min following administration.
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However, the majority of studies that examined effects of acute systemic NaBu
administration predominately used a higher 1.2 g/kg dose and found that it increases H3
and H4 acetylation levels 30 min later in whole hippocampal tissue (Ferrante et al., 2003;
Fischer et al., 2007; Gundersen & Blendy, 2009; Takuma et al., 2014).
There is evidence, however, that suggests NaBu alters global histone acetylation
in a time- and dose-dependent manner. For example, Schroeder et al. (2007) found that
a 1.2 g/kg dose of NaBu increased hippocampal H3 and H4 acetylation at 30 min, but this
increase returned to baseline levels 60 min following injection in mice. They also
demonstrated that NaBu dose-dependently increases H3 acetylation in the hippocampus,
such that a single 0.4 g/kg and 1.2 g/kg, but not 0.2 g/kg, dose of NaBu was required to
alter H3 and H4 acetylation levels 30 min following injection (Schroeder et al., 2007).
Together, these findings suggest that we potentially missed the timepoint in which any
histone alterations occurred by administering a lower dose of NaBu alone and by
assaying hippocampal tissue at a later timepoint. Nonetheless, our findings suggest that
a single dose of 0.6 g/kg NaBu is not sufficient to alter H2B, H3, or H4 acetylation levels
in DH.
Effect of Post-Training Treatment on Hippocampal Histone Acetylation
Although dosing and timing are important considerations for maximally assaying
global histone acetylation changes, another critical aspect that gives rise to HDACi’s
ability to alter cognition and histone acetylation is the presence of the stimuli itself. As
such, we next wanted to explore the possibility that our behaviorally effective doses of
MJM-1 and NaBu affect global histone acetylation patterns in the DH when administered
following successful completion of object training. This idea is supported previous studies
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demonstrating that when paired with an inefficient extinction protocol, i.p. administration
of the class I HDACi CI-994 enhances extinction learning at remote timepoints and
increases H3 acetylation in the hippocampus, but the effect on global acetylation changes
is seen only when the inhibitor is paired with extinction training (Gräff et al., 2014). These
data lend support to the possibility that HDACi such as NaBu and MJM-1 enhance longterm memory formation in a stimulus-dependent manner.
We expected to find an effect of object training alone, such that mice receiving a
post-training injection of DMSO would have increased histone acetylation relative to
Homecage controls. Furthermore, we also expected to see that mice receiving posttraining injections of either NaBu or 40 mg/kg MJM-1 would have potentiated levels of
histone acetylation relative to both Homecage control and DMSO-trained mice. However,
to our surprise, we did not find effects of object training or HDACi treatment on global
histone acetylation levels in the DH. These findings are largely inconsistent with previous
work from our lab demonstrating hippocampal histone acetyltransferase activity is
necessary for successful consolidation of object recognition memories (Zhao et al., 2012).
Moreover, work from other groups has demonstrated spatial and object memories in
rodents globally increase H2B, H3, and H4 acetylation in the hippocampus (Fischer et al.,
2007; Bousiges et al., 2010; Zhao et al., 2010; 2012; Fortress et al., 2014). The reason
for these descrepant effects remains unclear at the present time. Nonetheless, our
findings suggest that NaBu and MJM-1 do not enhance memory consolidation by altering
global histone acetylation levels within the DH.
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Effect on Hippocampal bdnf Expression
Finally, we examined the possibility that NaBu and MJM-1 enhance memory
consolidation by promoting the transcription of bdnf. We found that there is no effect of
MJM-1 treatment on DH expression of bdnf exons I and IV. However, we did find that
mice receiving NaBu treatment had increased bdnf exon I, but not exon IV, transcripts
relative to MJM-1 treated mice.
The lack of a treatment effect for MJM-1 on hippocampal bdnf expression is not
surprising considering this compound does not alter histone acetylation patterns in the
DH when administered alone or following object training. Nevertheless, previous reports
have demonstrated that numerous different HDACi promote bdnf transcription in the
rodent brain. For example, a single i.p. injection of NaBu immediately following object
training increased mRNA expression levels of bdnf exons I and IV relative to vehicletrained controls in the hippocampus (Intlekofer et al., 2013). Similarly, chronic
subcutaneous injections of NaBu increased BDNF immunoreactivity in hippocampus (Kim
et al., 2009). Another study compared the effects of class I-selective HDACi MS-275
against the class II-selective HDACi MC1568 in rat primary neurons and found that both
increased bdnf expression (Koppel & Timmusk, 2013). Although we only measured bdnf
exons I and IV in the hippocampus, alterations in expression levels of these transcripts
are regulated in part by chromatin remodeling through alterations to histone acetylation
(Cunha et al., 2010; Leal et al., 2015). As such, these transcripts serve as a reliable proxy
for examining how MJM-1 affects gene expression patterns relative to extant HDACi.
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Conclusions and Future Directions
The current study demonstrates that MJM-1 enhances spatial, but not object
recognition, memory consolidation, but does not affect hippocampal histone acetylation
levels or alter expression of bdnf exons I or IV. There are a number of future directions to
expand upon our behavioral and molecular findings. Future studies should examine
whether MJM-1 enhances spatial and object recognition memory when administered
chronically prior to object training. The present study administered MJM-1 immediately
following training in order to pinpoint the beneficial effects of MJM-1 to the consolidation
phase of memory formation. However, more translationally relevant results can be
obtained by examining whether lower doses of MJM-1 administered more frequently can
have similar beneficial effects on memory formation. Future behavioral work should also
assess the extent to which MJM-1’s memory-enhancing effects generalize to other spatial
memory tasks (i.e., Morris water maze).
It remains unclear at the present time how MJM-1 enhances spatial memory
consolidation in mice. However, our findings indicate that MJM-1 does not regulate
hippocampal histone acetylation or bdnf expression levels to promote spatial memory
formation. It is possible that MJM-1 has more localized effects on histone acetylation
levels rather than affecting bulk histone acetylation. Future studies should examine the
extent to which MJM-1 regulates synaptic plasticity gene expression and alters histone
acetylation at promoter regions of upregulated genes. It would also be interesting to
further gauge the extent to which MJM-1 affects chromatin remodeling by assaying
expression of the “writers” and “readers” of histone acetylation, including histone
acetyltransferases and bromodomains, respectively (Marmorstein & Zhou, 2014).

36

Moreover, it is also possible that MJM-1 regulates acetylation of non-histone substrates
such as transcription factors, nuclear receptors, and enzymes (Yang & Seto, 2007). In
this regard, future experiments could examine the extent to which MJM-1 modifies
expression transcription factors known to regulate memory formation (i.e., Creb, Egr-1,
AP-1). Although the molecular mechanisms underlying MJM-1’s beneficial effect on
spatial memory consolidation remain unclear at the present time, this work provides a
useful framework for how to better develop small-molecule HDACis that can be used to
improve cognition.
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APPENDIX
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Appendix Figure 1. Ability of MJM-1 to increase histone acetylation and inhibit HDAC activity.
(A-E) Representative images of histone H3 acetylation after treatment with MJM-1 or romidepsin.
DU145 tumor cells were treated with the indicated concentrations of MJM-1 or romidepsin for 24
hrs. Cells were labeled with DAPI (blue) to identify nuclei and stained for acetylated H3 (green).
Panel (A) shows cells treated with DMSO; (B) treated with 25 µM MJM-1; (C) treated with 50 µM
MJM-1; (D) treated with 100 µM MJM-1; and (E) treated with 10nM FK228. Scale bar = 50 m. (F)
Ability of HDAC1 (circles), HDAC2 (squares), HDAC3 (triangles), HDAC6 (diamonds), or HDAC8
(hexagons) to deacetylate peptides in the presence of either FK228 (filled symbols) or MJM-1 (open
symbols). All reactions were performed in triplicate with averages plotted and fitted to a
concentration response equation using non-linear regression (GraphPad Prism). The table lists the
concentration of either FK228 or MJM-1 needed to inhibit HDAC-catalyzed reactions by 50% (IC50).
Deacetylation was coupled to aminoluciferin and luciferase such that luminescence (arbitrary units,
au) linearly reflects deacetylase activity. Each reaction contained the same HDAC concentration
(0.5 nM) and indicated amounts of a HDACi. Uncertainties reflect 95% confidence intervals of the
curve fits.
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Appendix Figure 2. MJM-1 detected in the DH by LCMS-8040 mass spectrometry. A) Schematic of i.p.
administration and tissue collection procedure. The chromatograms (B-D) each depict a control internal
minpeak) on right. B,C) The 20 and 40 µg/g dose of MJM-1 (dashed
standard (black peak) on left and DH-10
MJM-1 (pink
arrow) is detected in the DH at 10 min following i.p. injection. D) The 40 µg/g dose can be detected in the DH
to a lesser extent at 30 min.
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